COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
Ivermectin study #50 of 63
1/11 Prophylaxis study
Chahla et al., NCT04701710 (Preprint)
Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan (Ivercar-Tuc)
Source   PDF   Share   Tweet
Prophylaxis RCT for ivermectin and iota-carrageenan in Argentina with 234 healthcare workers showing significantly lower cases with treatment. No paper is available yet but results are reported on clinicaltrials.gov.

Chahla et al., 1/11/2021, Randomized Controlled Trial, Argentina, South America, preprint, 1 author, dosage 12mg weekly.
risk of COVID-19 case, 94.7% lower, RR 0.05, p = 0.003, treatment 0 of 117 (0.0%), control 9 of 117 (7.7%), moderate/severe COVID-19.
risk of COVID-19 case, 84.0% lower, RR 0.16, p < 0.001, treatment 4 of 117 (3.4%), control 25 of 117 (21.4%), all cases.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 63 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit